Turner JR, Hill NL, Bhargava S, Madrigal C, Almeida DM, Mogle J. Age discrepancies across two decades: desiring to be younger is associated with daily negative affect over three waves of assessment. Prev Sci. 2023 Jul;24(5):901-10. doi: 10.1007/s11121-022-01386-0
Malcomson L, Dalal G, Vass C, Wright S, Gray E, Trenaman L, Payne K, Renehan A. Introducing PrefCoRe: quantifying and implementing patient preferences for the treatment of high-risk rectal cancer, including the new strategy of organ preservation. Poster presented at the 2020 Association of Coloproctology (ACPGBI) Virtual Conference; July 2020. [abstract] Colorectal Dis. 2020 Jul; 22(S1):41-2.
Mosquin PL, Rothman KJ. Reanalysis of reported associations of beryllium and lung cancer in a large occupational cohort. J Occup Environ Med. 2017 Mar;59(3):274-81. doi: 10.1097/JOM.0000000000000947
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Harshman RS, Richerson GT, Hadker N, Greene BL, Brown TM, Foster TS. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. J Occup Environ Med. 2008 Mar 1;50(3):359-65.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Talmud PJ, Hawe E, Miller GJ. Analysis of gene-environment interaction in coronary artery disease: lipoprotein lipase and smoking as examples. J Cardiovasc Med. 2002;3(1):6-9 Revie.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.
Dreyer NA, Loughlin JE, Lanes SF, Rothman KJ. Mortality among employees of a nuclear power company. J Occup Environ Med. 1988 Jan 1;30(12):988-9.